Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.98M rose 7.9% year over year, ahead of the -15.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 27.1% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +7.9% holds above the trailing-twelve-month pace of -15.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.98M+27.1% QoQ
Last fiscal yearDec 2025
$7M-20.4% YoY
LTMMar 2026
$7.15M-15.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.9%——
1 year-20.4%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
7M USD
Year-over-year change
-20.4%
4-year CAGR
+6.4%

Stock-Based Compensation vs competitors

How LRMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -15.9% is the 7th highest of 11, against a peer median of -7.9%.
  • Over three fiscal years its annual growth of +1.9% compares with a peer median of +77.5%.
LRMR Competitors
Stock-Based Compensation for LRMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$15.5M USD-21.9%-3.9%—
ALTAltimmune, Inc.LTM Mar 2026$15.44M USD+4.6%+25.7%42886.1%
ENGNenGene Holdings Inc.LTM Apr 2026$12.14M USD+60.2%+336.5%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$11.19M USD-19.1%+89.6%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$11.09M USD+34.6%+121.4%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$7.15M USD-15.9%+1.9%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$7.02M USD-5.4%+66.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$5.99M USD+37.2%+2.3%—
KRROKorro Bio, Inc.LTM Mar 2026$4.8M USD-10.4%+88.7%125.0%
AMRNAmarin Corporation plcLTM Mar 2026$3.95M USD-191.3%—1.8%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
Peer median (excluding LRMR) —-7.9%+77.5%100.0%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Depreciation & Amortization326K318K311K318K(1.35M)
Deferred Income Tax00000
Stock-Based Compensation5.47M6.62M7.62M8.8M7M
Change in Working Capital2.75M1.67M(2.51M)6.18M47.1M
Accounts Receivables00000
Inventory00000
Accounts Payables(974K)26K(403K)1.14M2.79M
Other Working Capital3.72M1.64M(2.11M)5.03M44.31M
Other Non-Cash Items(15K)(820K)(1.93M)(5.45M)(281K)
Operating Cash Flow(42.11M)(27.57M)(33.46M)(70.76M)(113.2M)
Capital Expenditures(333K)(100K)(164K)(515K)(91K)
Acquisitions (Net)(24.5K)90.86K000
Purchases of Investments(8.25M)(133.61M)(101.23M)(227.87M)(83.6M)
Sales of Investments32.75M42.75M134.75M143M184M
Other Investing Activities24.5K(90.86K)000
Investing Cash Flow24.17M(90.96M)33.35M(85.39M)100.31M
Debt Repayment00000
Common Stock Issued19.89M75.26M30K161.81M65.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00077K0
Financing Cash Flow19.89M75.26M30K161.88M65.09M
Effect of Forex Changes00000
Net Change in Cash1.95M(43.27M)(76K)5.74M52.19M
Free Cash Flow(42.44M)(27.67M)(33.62M)(71.28M)(113.29M)

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.